The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients
10.3760/cma.j.issn.1003-9279.2011.02.017
- VernacularTitle:HBV抗原定量对干扰素联合阿德福韦酯治疗HBeAg阳性慢乙肝的疗效预测
- Author:
Hai-Xia SUN
1
;
Hong CAO
;
Ka ZHANG
;
Xiao-An FANG
;
Gang LI
;
Qi-Huan XU
Author Information
1. 中山大学附属第三医院
- Keywords:
Hepatitis B;
Interferon Alfa-2a;
Adefovir dipivoxil;
Hepatitis B surface antigens
- From:
Chinese Journal of Experimental and Clinical Virology
2011;25(2):132-134
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the levels of HBsAg in predicting the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil( ADV ), in HBeAg-positive chronic hepatitis B patients.Methods This trial enrolled 62 HBeAg-positive chronic hepatitis B patients with detectable HBsAg for at least 6 months prior to screening, serum HBV DNA levels of at least 100 000 IU/ml. The efficacy assessment: viral suppression below 100 IU/ml. The patients with HBV DNA ≤ 100 IU/ml after 24 weeks therapy were divided into group A, in which monotherapy continued; While the rest were divided into group B, in which ADV was combined until week 48. In group B, at the end-of-treatment, the patients with HBV DNA ≤100 IU/ml were divided into group B1, the rest were divided into group B2. Results There was no significant difference on the beseline characteristics of patients between B1 and B2. There was significant difference on the levels of HBsAg at 12-week and 24-week between B1 and B2; while there was no significant difference on the levels of HBeAg. Conclusions The levels of HBsAg at 12-week and 24-week would be predictors to evaluate the efficacy of combined therapy in HBeAg-positive chronic hepatitis B patients.
